Endocrine Abstracts

Introduction: Skeletal fragility is a relevant and not-reversible complication of acromegaly, involving around 30-40% of patients since the disease diagnosis. Few studies have investigated the effects on skeletal health of medical therapies for acromegaly. We aim to investigate the frequency of incident vertebral fractures (i-VFs) in patients treated with Pasireotide Lar + Pegvisomant (study group), after at least 24 consecutive treatment months and to compare the i-VFs freque...